Characterizing the Adverse Event Profile of Semaglutide: A Comprehensive U.S. Food and Drug Administration Adverse Event Reporting System-Based Pharmacovigilance Study.
Semaglutide is primarily associated with gastrointestinal and metabolic adverse events consistent with its pharmacological effects; however, several less common but potentially important safety signals were identified, highlighting the need for continued pharmacovigilance and careful clinical monitoring in real-world u...